60results about How to "The prescription process is simple" patented technology

The invention relates to a bromhexine hydrochloride compound. The bromhexine hydrochloride compound is a crystal body and determined by using an X-ray powder diffraction method, and the characteristic peaks of the bromhexine hydrochloride compound are shown in a map in which 2theta plus or minus 0.2 degree is equal to 7.0 degrees, 10.9 degrees, 14.6 degrees, 15.8 degrees, 17.9 degrees, 21.1 degrees, 22.2 degrees, 23.4 degrees, 25.2 degrees, 29.3 degrees, 30.3 degrees, 33.4 degrees, 36.7 degrees and 39.6 degrees. The invention further provides a preparation and a pharmaceutical composition preparation which comprise the bromhexine hydrochloride compound, wherein the preparations can be prepared to form powder injection, freeze-dried powder injection, water injection and tablets. The formulation technology of the powder injection, freeze-dried powder injection, water injection and tablets of the bromhexine hydrochloride compound provided by the invention is simple in process, the stability of the bromhexine hydrochloride compound is obviously improved, and the safety and effectiveness of medication are improved.

Belonging to the technical field of medicine, the invention in particular relates to an antiallergic medicine syrup and a preparation method thereof. The medicinal composition contains desloratadine, a cosolvent, an antioxidant, a pH regulator and other pharmaceutically acceptable excipients. The syrup provided by the invention solves the difficult drug taking problem of patients with weak swallowing ability, and ensures simple process, controllable quality and improved stability, thus bettering meeting clinical needs.

The invention relates to the field of drug synthesis and preparation thereof, relates to a preparation method of an antibacterial drug, in particular to a stable cefodizime sodium composition preparation and a preparation method thereof. The present invention directly dissolves sterile cefodizime sodium in water, adds sterile potassium clavulanate to dissolve it completely, and obtains an aqueous solution of cefodizime sodium/clavulanate potassium, and adds hydroxypropyl-β to the aqueous solution. -Cyclodextrin (HP-β-CD) inclusion, sub-package, and freeze-drying to obtain Cefodizime Sodium/Clavulanate Potassium for Injection. The preparation method provided by the invention is simple, and the cefodizime sodium/clavulanic acid potassium salt is clathrated with hydroxypropyl-β-cyclodextrin, which increases the stability of the sterile cefodizime sodium drug and reduces its toxic and side effects , improve drug availability, and the preparation process is simple, suitable for industrial production.

The invention relates to the technical field of medicine, and particularly relates to a curcumin compound injection and an intravenous injection preparation thereof. The curcumin compound injection mainly comprises a curcumin compound, a solvent for injection and a small amount of pH regulator. The curcumin compound intravenous injection preparation is used only by mixing the curcumin compound injection and an emulsifier in a volume ratio of (1:5)-(1:250). After the curcumin compound injection and the emulsifier are mixed, the drug loading rate of the curcumin compound in the intravenous injection preparation is up to 1.5 mg/ml, and no crystal is separated out within 18 hours. The curcumin compound injection provided by the invention has a simple and safe preparation method and good stability, and is convenient for storage and transportation. The curcumin compound intravenous injection preparation has good stability due to the use of the emulsifier as a carrier solvent, and has no toxic and adverse effects. The invention solves the problem that the curcumin compound can not be prepared into the intravenous injection preparation and applied in clinics for a long period of time.

The invention relates to a curcumenol nanosuspension, and a preparation method and application thereof, and belongs to the field of pharmaceutical preparations. According to the invention, the curcumenol nanosuspension is prepared by adopting a precipitation method in combination with high-speed shearing and high-pressure homogenization. The prescription is optimized by using particle size and polydispersity index (PDI) as indicators, the form of the preparation is inspected by means of a transmission electron microscope, and the dissolution of the drug is inspected by means of in-vitro release experiments. The curcumenol nanosuspension provided by the invention is characterized in that the curcumenol nanosuspension comprises curcumenol, lecithin and PVP (polyvinyl pyrrolidone), wherein the mass ratio of the curcumenol to the lecithin to the PVP is 1:(0.4-0.6):(0.25-4); the particle size of drug in the suspension is 50-500 nm; and the curcumenol concentration in the suspension is 0.25-1 mg/ml. The nanosuspension preparation method provided by the invention is simple, controllable and suitable for industrial production, and improves the drug dissolution.

The invention relates to a gastrodine compound and a pharmaceutical composition thereof. The gastrodine compound is a crystal. The X-ray powder diffraction determines that the characteristic peaks are displayed when 2theta+/-0.2 degree is 4.5 degrees, 5.7 degrees, 7.9 degrees, 10.3 degrees, 11.2 degrees, 13.0 degrees, 16.4 degrees, 19.6 degrees, 21.2 degrees, 22.7 degrees, 24.8 degrees, 26.7 degrees, 29.6 degrees, 34.1 degrees and 35.3 degrees. The gastrodine compound has very high stability, thereby greatly enhancing the medicine safety. The invention also relates to a pharmaceutical composition preparation containing the gastrodine compound. The composition preparation can be a freeze-dried powder injection, injection, tablet or capsule. The gastrodine freeze-dried powder injection, injection, tablet or capsule preparation provided by the invention has the advantages of simple prescription technique, obviously higher stability, and enhances the medicine safety and effectiveness.

The invention provides a preparation method of nocathiacin freeze-dried powder injection. The method comprises the following steps of: (1) preparing liquor from nocathiacin, hydrophilic carriers, a pH regulator, an excipient and injection water, removing bacteria, and filtering and filling the liquor; and (2) performing freeze drying on the nocathiacin liquor. According to the freeze-dried powder injection prepared by the method, on the premise of enhancing the dissolvability of the nocathiacin, the consumption of the hydrophilic carriers such as a solubilizer and a cosolvent is reduced as much as possible; and the formulation and preparation are simple, the method is suitable for industrialized production, and the nocathiacin freeze-dried powder injection is high in stability and re-dissolution.

The invention provides a busulfan injection which is simple in prescription and stable in quality. The injection is prepared by the followings method: (1), dissolving busulfan into a mixed solvent of N, N-dimethyl acetamide and polyethylene glycol 400 in a volume ratio of (17-57):(83-43) to obtain a busulfan solution with concentration of 1mg/mL-7.5mg/mL; and (2), filtering and filling in a sterile manner, wherein in the dissolving process of the step (1), the temperature of the solution is 4 DEG C-25 DEG C, or/and inert gases are charged in an operation process until the solution is saturated. Not only is stability of the busulfan injection obtained by the preparation method disclosed by the invention improved, but also the safety of the injection after long-time storage is effectively ensured. Meanwhile, other substances or other chemical components are not introduced in the preparation process, so that the medication safety is ensured, and the drug cost is also lowered.

A provided daidzein-containing tablet composition comprises daidzein and arginine with the weight ratio of 1:2.5-4. The tablet composition comprises, in parts by weight, 16 parts of daidzein, 40-64 parts of arginine, 5-7 parts of a disintegrating agent, 14-38 parts of a diluent, 0.2-1.0 parts of a lubricant and 0.9-1.6 parts of an adhesive. By employing the above technical scheme, the water-soluble daidzein-containing tablet composition containing daidzein and arginine with the weight ratio of 1:2.5-4 is provided. The invention further provides a specific prescription and a preparation method. An added weak base enables daidzein to relatively well form a relatively stable easily-soluble salt, and thus improvement of dissolution rate is facilitated, and absorption by human body is facilitated. The technology is simple and the prescription quality is reliable, and batch production of the daidzein tablet can be realized.

The invention relates to a carbazochrome sodium sulfonate compound which is a crystal. The characteristic peak in a map through X-ray powder diffraction determination is 12.5 degrees, 17.4 degrees, 19.8 degrees, 21.0 degrees, 21.5 degrees, 23.4 degrees, 26.2 degrees, 26.8 degrees, 27.7 degrees, 29.0 degrees, 3.01 degrees, 31.6 degrees, 32.1 degrees, 35.0 degrees, 38.5 degrees, 40.3 degrees and 51.9 degrees at 2theta+/-0.2 degrees. The invention further provides a medical composition preparation containing the carbazochrome sodium sulfonate compound. The medical composition preparation is a freeze-dried powder injection, a water injection and a troche. The compound provided by the invention can be prepared in various medical forms and is extremely high in stability. The carbazochrome sodium sulfonate freeze-dried powder, water injection and troche preparations provided by the invention are simple in formulation and technology, the stability is remarkably improved, and the pharmaceutical safety and effectiveness are improved.

The invention belongs to the field of medicine chemistry and relates to obeticholic acid salts and a pharmaceutical composition thereof. Particularly, obeticholic acid salts includes obeticholic acid sodium salt, obeticholic acid potassium salt, obeticholic acid magnesium salt, obeticholic acid calcium salt and obeticholic acid ammonium salt. The invention further relates to a preparing method of obeticholic acid sodium salt, obeticholic acid potassium salt, obeticholic acid magnesium salt, obeticholic acid calcium salt and obeticholic acid ammonium salt, a pharmaceutical composition including the salts and medical application of the salts. The obeticholic acid salts have the advantages of being high in purity, stability and solubility property, show a good pharmacokinetics property and are suitable for being prepared into medicine products for use.

The invention relates to a preparation process of a compound dry powder inhaler for glucocorticoids and beta2 receptor agonists. The process comprises the following steps: (a) performing micronizationon glucocorticoids and beta2 receptor agonists; (b) mixing the micronized product in the step (a) with a drug carrier, or mixing the micronized product in the step (a) with a drug carrier and an additive; and (c) adding the composition in the step (b) into a sample handling room for handling, thereby obtaining the pharmaceutical composition of the dry powder inhaler. The sample handling room is an environment of which the humidity is 45-75% or an environment of which the pressure is not higher than 500Pa; the handling time is 2-72 hours; the glucocorticoids are mometasone furoate or pharmaceutically acceptable salts thereof; and the beta2 receptor agonists are indacaterol or pharmaceutically acceptable salts thereof. The process disclosed by the invention is simple, convenient to operateand low in production cost.

The invention relates to a cefodizime sodium and preparation method thereof, especially relates to a cefodizime sodium injection for treating microbe infection, and preferably relates to a freeze-drying powder injection. The cefodizime sodium injection of the present invention is mainly composed of active component cefodizime sodium and accessories such as mannitol and citric acid. The solvent in the injection of the present invention is injection water; the excipient in the freeze-drying powder injection is mannitol, and sodium hydroxide or hydrochloric acid is used for adjusting pH valve.

The invention discloses a pharmaceutical composition of palipeddone, belongs to medicine field, and relates to an antipsychotic pharmaceutical composition, wherein the pharmaceutical composition comprises palipeddone active component, controlled-release auxiliary material and other acceptable auxiliary material in pharmacy. The pharmaceutical composition provided by the invention solves the problem of difficult medicine taking by mental patients, and has advantages of simple technology, low cost and easy industrialization, and can better satisfy clinic needs.

The present invention relates to a preparation method, uses and a use method of a dexamethasone implant for kidney, wherein the dexamethasone implant comprises dexamethasone or dexamethasone acetate, a degradable polymer material, and a water soluble auxiliary material. The preparation method comprises: crushing various materials, mixing, carrying out micro-spheroidization, carrying out mold pressing molding, and heating for a certain time at a proper temperature to prepare the cylindrical implant with a diameter of 0.2-0.9 mm and a length of 0.8-4 mm. According to the present invention, the implant has characteristics of smooth surface and uniform drug release in vivo, wherein the time for releasing 90% of the drug is 1 month to 1 year; and the implant can be implanted into the renal sac through a drug implanting needle so as to treat nephrotic syndrome, nephritis and other chronic kidney diseases.